The synergistic effect of fluoxetine on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist

Journal of Neural Transmission

Volumn 103, Issue 1-2, 1996, Pages 131-146

  Maj, J ^a   Rogoz, Z ^a   Skuza, G ^a   Wcdzony K ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

5 ht agonists and antagonists; Dopamine release; Fluoxetine; Mk 801 induced hyperactivity; Rats

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ANTIDEPRESSANT AGENT; CHLORAMPHETAMINE; CITALOPRAM; CLOZAPINE; DIZOCILPINE; FLUOXETINE; KETANSERIN; METERGOLINE; MIANSERIN; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; PINDOLOL; RITANSERIN; SERTRALINE; SULPIRIDE; TROPISETRON; ZACOPRIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG INHIBITION; DRUG POTENTIATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; DIZOCILPINE MALEATE; DOPAMINE; DOPAMINE AGENTS; DRUG SYNERGISM; EXCITATORY AMINO ACID ANTAGONISTS; FLUOXETINE; MALE; MICRODIALYSIS; MOTOR ACTIVITY; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0030028251     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01292622     Document Type: Article

References (45)

1. Benloucif S, Galloway MP (1991) Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur J Pharmacol 200: 1-8
2. Blandina P, Goldfarb J, Craddock-Royal B, Green JP (1989) Release of endogenous dopamine by stimulation of 5-Hydroxytryptamine3 receptors in rat striatum. J Pharmacol Exp Ther 251: 803-809
3. Clineschmidt BV, Martin GE, Bunting PR, Papp NL (1982) Central symphatomimetic activity of (+)-5-methyl-10,H-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympatomimetic and apparent anxiolytic properties. Drug Dev Res 2: 135-145
4. Carlsson M, Svensson A (1990) Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems. Pharmacol Biochem Behav 36: 45-50
5. Fletcher A, Bill DJ, Bill SJ, Ciffe IA, Dover GM, Foster EA, Haskins JT, Jones D, Mansell HL, Reilly Y (1993) WAY 100135 - a novel, selective antagonist at presynaptic and postsynaptic 5-HT (1A) receptors. Eur J Pharmacol 237: 283-291
6. Glennon RA, Naiman NA, Pierson ME, Titeler M, Lyon RA, Weisberg E (1988) NAN190: an arylpiperazine analog that antagonizes the stimulus effects of the 5-HT,A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). Eur J Pharmacol 154: 339-341
7. Goodwin GM, Green AR (1985) A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1A, and 5-HT2 receptors. Br J Pharmacol 84: 743-753
8. Hiramarsu M, Cho AK, Nabeshima T (1989) Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur J Pharmacol 166: 359-366
9. Hjorth S, Carlsson A (1986) Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors? Eur J Pharmacol 129:131-138
10. Hjorth S, Sharp T (1990) Mixed agonist antagonists properties of NAN-190 at 5-HTJA receptors: behavioural and in vivo brain microdialysis studies. Life Sei 46: 955-963
11. Hoyer D (1988) Functional correlates of serotonin 5-HT[ recognition site. J Recept Res 8: 59-81
12. Hoyer D (1989) 5-Hydroxytryptamine receptors and effector coupling mechanisms in peripheral tissues. In: Fozard JR (ed) The peripheral action of 5-hydroxytryptamine. Oxford University Press, Oxford, pp 72-99
13. Hoyer D, Engel G, Kalkman HO (1985) Molecular pharmacology of 5-HT, and 5-HT2 recognition sites in rat and pig brain membranes. Radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[123I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin. Eur J Pharmacol 118: 13-23
14. Imperato A, Scrocco MG, Bacchi S, Angelucci L (1990) NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur J Pharmacol 187:555556
15. Jiang LH, Ashby CR, Kasser RJ, Wang RY (1990) The effect of intraventricular administration of the 5-HT3 receptor agonist 2-methyIserotonin on the release of dopamine in the nucleus accumbens: an in vivo chronocoulometric study. Brain Res 513: 156160
16. Leysen JE (1990) Gaps and peculiarities in 5-HT2 receptor studies. Neuropsychopharmacology 3: 361-369
17. Löscher W, Annies R, Hönack D (1991) The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci Lett 128: 191-194
18. Löscher W, Annies R, Hönack D (1993) Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioural effects in rats. Eur J Pharmacol 242: 263-274
19. Löscher W, Hönack D (1992) The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. Eur J Pharmacol 215: 199-208
20. Maj J, Rogöz Z, Skuza G (1982) Fluvoxamine, a new antidepressant drug, fails to show antiserotonin activity. Eur J Pharmacol 81: 287-292
21. Maj J, Rogöz Z, Skuza G (1991a) Antidepressant drugs increase the locomotor hyperactivity induced by MK-801 in rats. J Neural Transm [Gen Sect] 85: 169-179
22. Maj J, Rogöz Z, Skuza G (1991b) Locomotor hyperactivity induced by MK-801 in rats. Pol J Pharmacol Pharm 43: 449-458
23. Maj J, Rogöz Z, Skuza G (1992a) The effects of combined treatment with MK-801 and antidepressant drugs in the forced swimming test in rats. Pol J Pharmacol Pharm 44: 217-226
24. Maj J, Rogöz Z, Skuza G, Sowirîska H (1992b) The effect of antidepressant drugs on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist. Neuropharmacology 31: 685-691
25. Morelli M, Di Chiara G (1990) MK-801 potentiates dopaminergic Dl but reduces D2 responses in thé 6-hydroxydopamine model of Parkinson's disease. Eur J Pharmacol 182: 611-612
26. Papp M, Moryl E (1993) Similar effect of chronic treatment with imipramine and NMDA antagonists CGP 37849 and MK-801 in a chronic mild stress model of depression in rats. Eur Neuropsychopharmacol 3: 348-349
27. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, New York
28. Pierce PA, Peroutka SJ (1988) Analysis of 5-HTj binding site subtypes and potential functional correlates. In: Rech RH, Gudelski GA (eds) 5-HT agonists as psychoactive drugs. NPP Books, Ann Arbor, p 11
29. Porsolt RD, Berlin A, Blavet N, Deniel M, Jalfre M (1979) Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol 57: 201-210
30. Rao TS, Kim HS, Lehman J, Martin MM, Wood PL (1990) Interactions of phencyclidine receptor agonist MK-801 with dopaminergic system: regional studies in the rat. J Neurochem54: 1157-1162
31. Reynolds IJ, Miller RJ (1988) Tricyclic antidepressant block N-methyl-D-aspartate receptors: similarities to the action of zinc. Br J Pharmacol 95: 95-102
32. Richardson BP, Engel G, Donatsch P, Stadier PA (1985) Idenfication of serotonin Mreceptor subtypes and their specific blockade by a new class of drugs. Nature 316: 126-131
33. Routledge C, Gurling J, Wright IK, Dourish CT (1993) Neurochemical profile of the selective and silent 5-HT1A receptor antagonist WAY 100135: an in vivo microdialysis study. Eur J Pharmacol 239: 195-202
34. Smith WW, Sancilio LF, Owera-Atepo JB, Naylor RJ, Lambert L (1988) Zacopride, a potent 5-HT3 antagonist. J Pharm Pharmacol 40: 301-302
35. Sokoloff P, Martres M-P, Giros B, Bouthenet M-L, Schwartz J-C (1992) The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem Pharmacol 43: 659-666
36. Tricklebank MD, Singh L, Oies RL, Preston C, Iversen SD (1989) The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptors. Eur J Pharmacol 167: 127-135
37. Trullas R, Skolnick P (1990) Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185: 1-10
38. Wedzony K, Gofembiowska K, Maj J (1991) A search for the effects of NMDA on the release of dopamine from the rat nucleus caudatus. In: Rollema H, Westerink BHC, Drijfhou WJ (eds) Monitoring molecules in neuroscience. University Center of Pharmacy, Groningen, pp 321-324
39. Wedzony K, Gotembiowska K, Zazula M (1994) Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to modu-lation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats. Naunyn Schmiedebergs Arch Pharmacol 350: 555-562
40. Wedzony K, Klimek V, Goiembiowska K (1993) MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D, receptors. Brain Res 622: 325-329
41. Whitton PS, Biggs CS, Pearce BR, Fowler LJ (1992) MK-801 increases extracellular 5-hydroxytryptamine in rat hippocampus and striatum in vivo. J Neurochem 58: 1573-1575
42. Wong DT, Bymaster FP, Horng JS, Molloy BB (1975) A new selective inhibitor for uptake of serotonin into synaptosomes of the rat brain: 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenyl propylamine. J Pharmacol Exp Ther 193: 801-811
43. Wong DT, Bymaster FP, Reid LP, Threlkeld PG (1983) Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem Pharmacol 32:1287-1293
44. Wong EHF, Kemp JA, Pristley T, Knight AR, Woodruff GN, Iversen LL (1986) The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sei USA 83: 7104-7108
45. Wong EHF, Knigh AR, Woodruff GN (1988) [3H]MK-801 labels a site on the N-methylD-aspartate receptor channel complex in the rat brain membranes. J Neurochem 50: 274-281